

Case Docket No. WWF L53.001APC
Date: Accust 5, 2002

I hereby certify that this correspondence and all

Patents, Washington, D.C. 20231, on

marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for

August 5, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Küpper, et al.

Appl. No.

10/009,040

Filed

October 23, 2001

For

USE OF COXSACKIE

VIRUSES FOR IMPROVING

TRANSFECTION OF CELLS

Examiner

UNKNOWN

Group Art Unit:

UNKNOWN

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are the following:

- (X) A Supplemental Information Disclosure Statement;
- (X) A PTO Form 1449 listing nine (9) references, copies of which are enclosed; and
- (X) A return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Mark R. Benedict

Registration No. 44,531 Attorney of Record AUG 20 2002 RECHNOLOGY CENTER 1700 WWELL53.001APC



IN THE UNITED STATES PATENT AND TRADEMARK O

Applicants	:	Küpper, et al.)	Group Art Unit UNKNOWN
App. No.	:	10/009,040)	A GOOD TO
Mailed	:	October 23, 2001)	RECHNOL
For	:	USE OF COXSACKIE VIRUSES FOR IMPROVING TRANSFECTION OF CELLS)	ECEIVED 2002
Examiner	:	UNKNOWN)	ER 1700

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing nine (9) references that are also enclosed. This Supplemental Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Mark R. Benedict

Registration No. 44,531

Attorney of Record

620 Newport Center Drive, Sixteenth Floor

Newport Beach, CA 92660

(949) 760-0404

٠						s	HEET'1 C				
FORMI	PTO-1449 U.S. DEPARTMEN [*] PATENT AND TR	OF COMMERCE ADEMARK OFFICE	ATTY. DOCKET NO. WWELL53.001APC	APPLICA 10/009	ATION NO. 7 ,040	RCE.	7.				
INF	FORMATION DISCLOSURE STATE	MENT			70	()	LA				
PE	BY APPLICANT		APPLICANTS Küpper, et al.		APPLICATION NO. 10/009,040 AUG. 2 2000 GROUP ART UNIT ER 1000/2500						
6 S	SE SEVERAL SHEETS IF NECESS	ARY)	FILING DATE October 23, 2001	ART UNIT COWN	RT UNIT ER 1600/a						
9 2002 E						728	Ø				
ADENAM OF			U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS		(IF APPR	DATE OPRIATE				
							20				
						2 2 30	EO				
							四				
	·					2002 ENTER	一				
						E 23					
		FC	DREIGN PATENT DOCUMENTS			700					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	I	LATION				
						YES	NO				
	<u> </u>										
		 									
		<u> </u>			<u> </u>	<u></u>	<u> </u>				
EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)										
	Barr, et al., "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus," Gene Therapy, Volume 1, pp. 51-58, (1994).										
	Bowman, et al., "Bafilomycins: A class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells," Proceedings National Academy of Sciences, USA, Volume 85, pp. 7972-7976, dated November 19988.										
	Drose, et al., "Inhibitory Effect of Modified Bafilomycins and Concanamycins on P- and V-Type Adenosinetriphosphatases," American Chemical Society, Biochemistry, Volume 32, pp. 3902-3906, (1993).										
	Felgner, et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," Proceeding National Academy of Sciences, USA, Volume 84, Biochemistry, pp. 7413-7417, dated November 1987.										
	virus in mammalian cells," Procee	andolf, et al., "Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: Full-lengh reverse-transcribed recombinant cDNA generate infection rus in mammalian cells," Proceedings National Academy of Sciences, USA, Volume 82, Medical Sciences, pp. 4818-4822, dated July 1985.									
	Klump, et al., "Complete Nucleotide Sequence of Infectious Coxsackievirus B3 cDNA: Two Initial 5' Uridine Residues Are Regained during Plus-Strand RNA Synthesis," Journal of Virology, American Society for Microbiology, pp. 1573-1583, dated April 1990.										
	Nabel, et al., "Recombinant Gene Expression in vivo Within Endothelial Cells of the Arterial Wall," Science, Volume 244, pp. 1342-1344, dated June 16, 1989.										
	Nabel, et al., "Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall," Science Reports, Volume 249, pp. 1285-1288, dated September 14, 1990.										
]	 Wagner, et al., "Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Towar a synthetic virus-like gene-transfer vehicle," Proceedings National Academy of Sciences, USA, Volume 89, Biochemistry, pp. 7934-7938, September 199 										

H:\DOC\$\CM\$\CM\$-2882.DOC\dns 080502

EXAMINER	DATE CONSIDERED							
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.								